News
NSPR
0.8800
-4.86%
-0.0450
Weekly Report: what happened at NSPR last week (0601-0605)?
Weekly Report · 2h ago
InspireMD Shareholders Approve Stock Increase and Board Slate
TipRanks · 4d ago
InspireMD shareholders approve increase in authorized common shares to 250 million
PUBT · 4d ago
Weekly Report: what happened at NSPR last week (0525-0529)?
Weekly Report · 06/01 09:35
InspireMD Director Makes Bold Insider Move Signaling Growing Confidence
TipRanks · 05/30 02:02
InspireMD director Paul Stuka acquires 20,000 common shares valued at $17,500
PUBT · 05/29 20:06
Weekly Report: what happened at NSPR last week (0518-0522)?
Weekly Report · 05/25 09:37
InspireMD chair Paul Stuka to retire, won’t seek board reelection in 2027
PUBT · 05/22 20:07
Top InspireMD Executive Makes Notable Move With Latest Stock Sale
TipRanks · 05/22 02:10
Weekly Report: what happened at NSPR last week (0511-0515)?
Weekly Report · 05/18 09:37
InspireMD Insider Makes Bold Move With Fresh Share Purchase
TipRanks · 05/16 02:06
Top Executive Makes Bold Move With Fresh InspireMD Stock Purchase
TipRanks · 05/14 02:10
InspireMD CEO Marvin Slosman acquires 21,000 shares valued at $25,200
PUBT · 05/13 21:01
InspireMD Insider Makes Bold New Bet on the Company’s Future
TipRanks · 05/13 02:04
InspireMD director Paul Stuka buys common shares worth $87,125.56
PUBT · 05/12 23:36
Weekly Report: what happened at NSPR last week (0504-0508)?
Weekly Report · 05/11 09:35
InspireMD Balances Fast Growth With U.S. Setback
TipRanks · 05/11 00:21
Insiders Make Bold Moves as InspireMD Directors Load Up on Shares
TipRanks · 05/09 02:10
InspireMD director Scott R. Ward acquires common shares worth $102,125
PUBT · 05/08 21:08
InspireMD director Paul Stuka acquires 7,895 shares worth $9,053.79
PUBT · 05/08 21:06
More
Webull provides a variety of real-time NSPR stock news. You can receive the latest news about Inspiremd through multiple platforms. This information may help you make smarter investment decisions.
About NSPR
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.